H.C. Wainwright has reaffirmed a Buy rating and a $30.00 price target for Olema Pharmaceuticals (NASDAQ: OLMA), following the presentation of preclinical data at a recent symposium.
The data included findings on the company’s KAT6 inhibitor, OP-3136, which is being developed for HR+/HER2- breast cancer treatment.
Olema presented three preclinical data posters at the EORTC-NCI-AACR Symposium, showcasing various combinations of OP-3136 with other cancer drugs.
The study results indicated that OP-3136, when combined with fulvestrant, palazestrant, or CDK4/6 inhibitors, displayed increased inhibition of T47D cells, particularly noting the substantial inhibition with OP-3136 and ribociclib.
The triple combination of OP-3136, palazestrant, and ribociclib led to even greater inhibition compared to the doublet combinations. In a xenograft model derived from T47D cell lines, the combination of OP-3136 and palazestrant resulted in a more significant tumor volume reduction than combinations with fulvestrant.
The research also compared OP-3136’s efficacy with Pfizer (NYSE:)’s PF-07248144, another agent in the same therapeutic category. OP-3136 showed greater single-agent activity as well as higher efficacy in combination with palazestrant and ribociclib, leading to a more pronounced tumor volume reduction than combinations using PF-07248144.
This was also observed in a patient-derived xenograft model, ST340, where the triple combination involving OP-3136 yielded the most significant tumor volume decline.
In other recent news, Olema Pharmaceuticals has been making significant strides with promising preclinical findings for its KAT6 inhibitor, OP-3136, presented at the EORTC-NCI-AACR Symposium.
Goldman Sachs reaffirmed its Buy rating on the company, maintaining a steady price target of $27.00. The studies demonstrated OP-3136’s anti-tumor activity, showing further improvement when used with endocrine therapy and CDK4/6 inhibitors.
In addition, the company released new data from a Phase 1a/1b study known as EMBER for imlunestrant, a drug under development for certain breast cancer populations. The study showed promising results, particularly in ESR1-Wild Type breast cancers, suggesting that imlunestrant may offer an improved treatment option for this patient subset.
Olema Pharmaceuticals has also increased its loan capacity to $100 million, double the previous limit of $50 million, as per a recent amendment to its Loan and Security Agreement with Silicon Valley Bank.
The firm now has immediate access to $25 million, with an additional $25 million contingent upon achieving specific milestones related to a pivotal Phase 3 clinical trial of another drug candidate, palazestrant, in combination with ribociclib. The remaining $50 million is subject to the bank’s approval.
InvestingPro Insights
Recent InvestingPro data provides additional context to Olema Pharmaceuticals’ (NASDAQ:OLMA) financial position and market performance. The company’s market capitalization stands at $681.56 million, reflecting investor sentiment following the recent preclinical data presentation. Despite the positive research findings and H.C. Wainwright’s optimistic outlook, OLMA’s stock has experienced volatility, with a 3-month price total return of -19.64% as of the latest data.
InvestingPro Tips highlight that Olema holds more cash than debt on its balance sheet, which could be crucial for funding ongoing research and development efforts, including the advancement of OP-3136 towards IND filing and clinical trials. However, the company is not currently profitable, with a negative P/E ratio of -6.17 over the last twelve months as of Q2 2024. This aligns with the early-stage nature of Olema’s drug development pipeline.
Investors should note that analysts have revised their earnings expectations downward for the upcoming period, which may reflect the ongoing investments required for drug development. The company’s next earnings date is set for November 5, 2024, which could provide further insights into the financial implications of its research progress.
For those interested in a deeper analysis, InvestingPro offers 5 additional tips for OLMA, providing a more comprehensive view of the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
